Methods for treating Alzheimer's disease

1. A method of treating, delaying the onset of, slowing the progression of, or alleviating at least one symptom of Alzheimer's disease comprising administering to a patient a pharmaceutical composition comprising an effective amount of an inhibitor of ATase1 and/or ATase2, wherein the inhibitor of ATase1 and/or ATase2 is a compound selected from the compounds having the following formula:

wherein:

R 1 , R 2 , R 3 , R 4 , and R 7 are each independently selected from hydrogen, halogen, —OH, —OR 9 , —SH, —SR 9 , —NH 2 , —NHR 9 , —NR 9 R 10 , and C 1 -C 10 alkyl, wherein R 9 and R 10 are independently selected from C 1 -C 5 alkyl;

R 8 is selected from hydrogen, halogen, —OH, —NH 2 , and —SH, or is absent;

R 5 and R 6 are each independently selected from hydrogen, halogen, —OH, —OR 9 , —SH, —SR 9 , —NH 2 , —NHR 9 , —NR 9 R 10 , and C 1 -C 10 alkyl, wherein R 9 and R 10 are independently selected from C 1 -C 5 alkyl; or R 5 and R 6 together are

wherein R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen, halogen, —OH, —OR 9 , —SH, —SR 9 , —NH 2 , —NHR 9 , —NR 9 R 10 , and C 1 -C 10 alkyl, wherein R 9 and R 10 are independently selected from C 1 -C 5 alkyl;

X 1 is selected from N, NH, and O;

X 2 is selected from N and O;

X 3 is selected from —OH, ═O, —NH 2 , ═NH, —SH, and ═S; and

wherein the X 1 to carbon a (C a ) bond and the carbon b (C b ) to carbon c (C c ) bond are both double bonds, or the C a to C b bond is a double bond;

or pharmaceutically acceptable salts thereof;

whereby Alzheimer's disease in the patient is delayed in onset, or slowed in progression, or whereby at least one symptom of Alzheimer's disease is alleviated.

2. The method of claim 1 , wherein the inhibitor of ATase1 and/or ATase2 is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.